CD83 CAR T cells

CD83 CAR T cells are genetically engineered T cells expressing a chimeric antigen receptor (CAR) that specifically recognizes the CD83 protein. CD83 is markedly expressed on allo-activated conventional CD4+ T cells and proinflammatory dendritic cells, which contribute to graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), as well as on acute myeloid leukemia (AML) blasts. The CAR, typically incorporating CD3ζ and a costimulatory domain (such as 41BB), enables T cells to selectively target and eradicate CD83+ pathogenic cells. This leads to durable prevention or treatment of GVHD by increasing the ratio of regulatory T cells to activated T cells, and elimination of AML blasts[1][3][5][6]. The therapy is autologous (using patient’s own cells), and offers a novel, cell-based approach distinct from conventional pharmacologic immunosuppression[5][6]. CD83 CAR T cells are under investigation for the treatment of relapsed or refractory AML and for prevention and treatment of GVHD[1][4][5].

Brand names

CD83 CAR T cellsCD-83 CAR T cellsCD 83 CAR T cells

Other names

CD83-targeted CAR T cellsCD-83-targeted CAR T cellsCD 83-targeted CAR T cellsanti-CD83 CAR T cellsanti-CD-83 CAR T cellsanti-CD 83 CAR T cellsCD83 chimeric antigen receptor T cellsCD-83 chimeric antigen receptor T cellsCD 83 chimeric antigen receptor T cells